Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > J Korean Cancer Assoc > Volume 31(4); 1999 > Article
Original Article
Prognostic Value of PCNA , c-erbB-2 , c-fos in Patients with Non-small Cell Lung Cancer
Yi Hyeong Lee, Joong Bae Ahn, Dong Hwang Shin, Soon Won Hong, Jeong Yeon Shim, Kyung Young Jung, Se Kyu Kim, Joon Chang, Joo Hang Kim, Won Youn Lee, Byung Soo Kim, Sung Kyu Kim
Journal of the Korean Cancer Association 1999;31(4): 678-685.
1Department of Pulmonary Medicine, Ajou University School of Medicine, Korea.
2Department of Internal Medicine, Yonsei University College of Medicine, Korea.
3Department of Pathology, Yonsei University College of Medicine, Korea.
4Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Korea.
5Department of Applied Statistics, Yonsei University College of Business, Korea.
6Yonsei Cancer Center; Korea.
7Department of Pathology, Pochon Joongmun Medical College, Korea.
8The Institute of Chest Diseases, Yonsei University College of Medicine, Seoul, Korea.
  • 2,939 Views
  • 14 Download
  • 0 Crossref
  • 0 Scopus
prev next

PURPOSE
Oncogenes, tumor suppressor genes, and growth variables of tumors are important in the assessment of prognosis in lung cancer. The expression of PCNA, c-erbB-2 (HER-2/neu), and c-fos oncoprotein and their prognostic implications in surgically resected patients with non-small cell lung cancer were evaluated.
MATERIALS AND METHODS
Seventy patients with non-small cell lung cancer were included and PCNA, c-erbB-2 and c-fos overexpression were evaluated by immunohistochemical stain using paraffin-embedded tissue.
RESULTS
The mean proportion of PCNA positive cells was 18.6%, and there was no significant difference according to cell type and stage. The median survival time was significantly shorter in the group with high PCNA expression (>10%) as compared with the group with low PCNA expression (<10%) (37 months vs 16 months). Four (6.3%) of 64 cases demonstrated c-erbB-2 positivity. These were all adenocarcinoma cases. c-fos protein was only rarely overexpressed (1/51).
CONCLUSION
PCNA expression was shown to be a useful prognostic parameter in resected non-small cell lung cancer while c-erbB-2 and c-fos oncoprotein were infrequently expressed.

  • Cite
    CITE
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Prognostic Value of PCNA , c-erbB-2 , c-fos in Patients with Non-small Cell Lung Cancer
    J Korean Cancer Assoc. 1999;31(4):678-685.
    Close
Related articles

Cancer Res Treat : Journal of the Korean Cancer Association
Close layer
TOP